Two years ago private device makers’ ardour for going public via a merger with a SPAC was at fever pitch. As market sentiment sank into despondency over the course of last year, enthusiasm slackened and medtech Spac deals slowed from a flood to a trickle, Evaluate reports.
The performance of the 26 medtechs that went public via SPAC deals over the last two years has been woeful. Only one has seen its enterprise value exceed the figure promised when the Spac merger was announced, and four now trade at a negative enterprise value, indicating that these groups are trading below cash.
Device makers started stepping away from SPAC deals in the final quarter of 2021, but signs were already mounting that some investors were getting cold feet. A big signal here is redemption rates. Read more.
